# Unlearn.AI

According to OpenAITools.app telemetry verified on 2026-11-11, Unlearn.AI (unlearn.ai) is an AI platform indexed under AI Healthcare generating 17.11K monthly visits with a month-over-month traffic delta of -8.23K (-32.5%). Its primary geographic market is United States (69.4% traffic share), and it operates on a Contact for Pricing pricing model. Top competing alternatives by monthly volume include Ubie (2.94M visits/mo), Heidi (2.18M visits/mo), Doctronic AI Doctors + Human Doctors (1.13M visits/mo).

AI-generated digital twins that make clinical trials smaller, faster, and more informative

## Key Telemetry & Specifications

| Metric | Value |
| :--- | :--- |
| Tool Name | Unlearn.AI |
| Handle | unlearn-ai |
| Status | active |
| Origin | official |
| Maintenance | active |
| Official Domain | unlearn.ai |
| Website URL | https://unlearn.ai |
| Categories | AI Healthcare, AI Research Tool, AI Predictions, AI Models, AI For Data Analytics |
| Pricing Model | Contact for Pricing |
| Monthly Visits | 17,107 |
| MoM Traffic Change | -8,233 |
| MoM Growth Rate | -32.5% |
| Primary Market | United States |
| Market Share | 69.4% |
| Direct Visits | 7,493 |
| Organic Search Visits | — |
| Social Visits | — |
| Referral Visits | 1,401 |
| Email Visits | 653 |
| Review Score | 4.4 |
| Saved Count | 1 |
| Supported Platforms | Website |
| Billing Platforms |  |
| Attributes | Features: Website; Pricing: Contact for Pricing |
| Tags | AI, Digital Twins, Clinical Trials, Clinical Research, Drug Development, Healthcare, Machine Learning, Predictive Analytics, Simulation, Data-Driven Decision Making |

## Overview

Unlearn.AI works with biopharma sponsors and clinical research teams at three points in a trial's lifecycle: before the protocol is finalized, while the study is running, and after readout. In design, teams model the patients they expect to enroll and pressure-test sample size, eligibility criteria, endpoints, and comparators before locking the protocol. The company's PROCOVA method — described as EMA-qualified and FDA-supported — applies twin-based covariate adjustment to reduce sample size in randomized controlled trials while holding statistical power, or to increase power without adding patients.

Mid-study, Unlearn supports pre-specified twin-based analyses that tighten interim estimates without enrolling anyone new, and lets teams re-run design scenarios when new evidence — a competitor readout, a fresh publication, or blinded data drifting from assumptions — changes the picture. After a study reads out, digital twins are used to contextualize population, endpoints, and variability, improving sensitivity across endpoints and helping teams re-evaluate historical trial data with regulatory-aligned methods.

Unlearn publishes concrete case outcomes: a 20% sample-size reduction built into a Phase 1/2 design with roughly $2M in savings, a 33% smaller control arm and four-plus months of enrollment time saved in a re-analysis of completed Phase 3 trials from a top-5 global sponsor, and a completed Phase 3 ALS trial re-analyzed to keep full power with 92 fewer participants. The company partners with sponsors including Trace Neuroscience, QurAlis, Acumen Pharmaceuticals, SOLA Biosciences, VectorY Therapeutics, and CHDI Foundation, and states it works with top global pharma companies. Unlearn does not publish list pricing; engagements are scoped through direct contact.

## Pricing & Plans

Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team.

## Key Features & Capabilities

- **AI-generated patient digital twins:** Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
- **PROCOVA design and analysis method:** A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
- **Trial design scenario modeling:** Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
- **Interim and readout analysis support:** Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
- **Externally controlled study design:** Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.

## Primary Use Cases

- **Right-size a Phase 1/2 protocol before it locks (Clinical development lead):** Simulate expected enrollees against real eligibility criteria, then evaluate sample size and endpoints to lock in a smaller, lower-cost design before governance review.
- **Add pre-specified twin analyses at interim (Biostatistician):** Raise power at interim looks and in subgroup analyses without adding participants by incorporating twin-based covariate adjustment into the statistical analysis plan.
- **Recover more signal from completed trials (Program strategist):** Re-analyze finished studies with digital twins to contextualize variability, improve endpoint sensitivity, and inform whether and how the program continues.
- **Strengthen single-arm evidence (Rare-disease sponsor):** Use digital twins as the comparator in open-label or single-arm studies where randomization is impractical, tightening the evidence for regulators.

## Strengths

- Digital twins are generated from data already collected, so no extra patients are required to gain information
- Publicly reported, quantified outcomes — sample-size reductions, cost savings, and enrollment time saved — rather than only qualitative claims
- Covers the whole trial lifecycle: design, interim, and readout, not just one decision point
- Named collaborations with biotech and pharma sponsors, plus regulatory-aligned methodology
- Awards and press coverage indicate an active, growing organization

## Limitations

- Pricing is not published, so budgeting requires a direct sales conversation
- The value proposition depends on regulatory acceptance of twin-based methods, which varies by agency and indication
- Best suited to sponsors with existing clinical data and statistical teams; not a self-serve tool
- Public metrics come from specific studies and may not transfer directly to other indications

## Frequently Asked Questions

### Is Unlearn.AI free?
No. Unlearn.AI is an enterprise clinical-development technology company that does not publish list pricing. Engagement is scoped with the team, so cost depends on the study or program involved.

### What exactly is a digital twin?
Unlearn describes a digital twin as an AI-generated forecast of one participant's clinical outcomes. Generated from a patient's baseline data, it can serve as a virtual comparator or add information per enrolled participant.

### Which trial stages does it support?
Three: before the protocol is finalized (design), from first patient in through readout (in progress), and after readout when teams want to unlock more from data already collected.

### Does using digital twins replace real trial participants?
No. Digital twins are used alongside enrolled participants — for example, to reduce the size of a control arm or raise statistical power. They are an analytical and design aid, not a substitute for human trials.

### Who is Unlearn.AI built for?
Biopharma sponsors, clinical development and biostatistics teams, and clinical research organizations. It is a partner-led, enterprise service rather than a self-serve software product.

### What is Unlearn.AI's monthly traffic and growth trend?
Unlearn.AI currently receives 17.11K monthly visits, with a month-over-month traffic change of -8.23K (-32.5% growth rate). Its primary source market is United States (69.4% share), including 7.49K direct visits/mo and — organic search visits/mo.

### Is Unlearn.AI free? What is its pricing model?
Unlearn.AI operates on a Contact for Pricing pricing model. Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team. Supported billing and checkout platforms include: not listed.

### What are the best Unlearn.AI alternatives in 2026?
Based on OpenAITools.app category traffic and feature fit, the top five alternatives to Unlearn.AI are: 1. Ubie (2.94M visits/mo); 2. Heidi (2.18M visits/mo); 3. Doctronic AI Doctors + Human Doctors (1.13M visits/mo); 4. Freed AI Medical Scribe (1.03M visits/mo); 5. Carepatron (932.07K visits/mo).

### Which platforms and core AI capabilities does Unlearn.AI support?
Unlearn.AI is classified under AI Healthcare, AI Research Tool, AI Predictions, AI Models, supports the following platforms: Website, and its core capability tags include: AI, Digital Twins, Clinical Trials, Clinical Research, Drug Development, Healthcare.

## Alternatives

| Tool Name | Monthly Visits | Pricing Model | Compare |
| :--- | :--- | :--- | :--- |
| [Ubie](https://openaitools.app/tool/ubie) | 2,941,054 | Free | [Compare](https://openaitools.app/compare/ubie-vs-unlearn-ai) |
| [Heidi](https://openaitools.app/tool/heidi) | 2,184,693 | Freemium, Free Trial, Paid, Contact for Pricing | [Compare](https://openaitools.app/compare/heidi-vs-unlearn-ai) |
| [Doctronic AI Doctors + Human Doctors](https://openaitools.app/tool/doctronic-ai-doctors-human-doctors) | 1,131,516 | Freemium | [Compare](https://openaitools.app/compare/doctronic-ai-doctors-human-doctors-vs-unlearn-ai) |
| [Freed AI Medical Scribe](https://openaitools.app/tool/freed-ai-medical-scribe) | 1,030,047 | Free Trial, Paid, Contact for Pricing | [Compare](https://openaitools.app/compare/freed-ai-medical-scribe-vs-unlearn-ai) |
| [Carepatron](https://openaitools.app/tool/carepatron) | 932,071 | Freemium | [Compare](https://openaitools.app/compare/carepatron-vs-unlearn-ai) |
| [Lecturio](https://openaitools.app/tool/lecturio) | 901,272 | Freemium | [Compare](https://openaitools.app/compare/lecturio-vs-unlearn-ai) |
| [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | Free Trial | [Compare](https://openaitools.app/compare/dr-oracle-vs-unlearn-ai) |
| [Upheal](https://openaitools.app/tool/upheal-io) | 347,782 | Freemium, Free Trial, Contact for Pricing | [Compare](https://openaitools.app/compare/unlearn-ai-vs-upheal-io) |
| [Vocal Image](https://openaitools.app/tool/vocalimage-app) | 341,754 | Freemium | [Compare](https://openaitools.app/compare/unlearn-ai-vs-vocalimage-app) |
| [ScanSkinAI](https://openaitools.app/tool/scanskinai) | 265,770 | Freemium, Paid | [Compare](https://openaitools.app/compare/scanskinai-vs-unlearn-ai) |
| [Overjet](https://openaitools.app/tool/overjet-ai) | 256,150 | Contact for Pricing | [Compare](https://openaitools.app/compare/overjet-ai-vs-unlearn-ai) |
| [Lyrebird Health](https://openaitools.app/tool/lyrebird-health) | 222,779 | Freemium, Contact for Pricing | [Compare](https://openaitools.app/compare/lyrebird-health-vs-unlearn-ai) |

---
Source: https://openaitools.app/tool/unlearn-ai